Table 1.
Clinicopathological variables and NEAT1_2 expression in breast cancer screening cohort (n = 74). The Chi square test (χ2-value) was used to calculate p-values.
| Variable, n(%) | NEAT1_2 expression | p | Total (n = 74) | ||||
|---|---|---|---|---|---|---|---|
| 0 (n = 25) | 1 (n = 20) | 2 (n = 23) | 3 (n = 6) | ||||
| Age at diagnosis | <55 | 10 (34.5) | 8 (27.6) | 8 (27.6) | 3 (10.3) | 0.920 | 29 (39.2) |
| ≥55 | 15 (33.3) | 12 (26.7) | 15 (33.3) | 3 (6.7) | 45 (60.8) | ||
| Histologic grade | 1 | 10 (55.6) | 5 (27.8) | 3 (16.7) | 0 (0.0) | 0.027* | 18 (24.3) |
| 2 | 8 (34.8) | 9 (39.1) | 5 (21.7) | 1 (4.3) | 23 (31.1) | ||
| 3 | 7 (22.2) | 6 (18.2) | 15 (45.5) | 5 (15.2) | 33 (44.6) | ||
| Tumor type | NST | 20 (29.9) | 20 (29.9) | 22 (32.8) | 5 (7.5) | 0.156 | 67 (90.5) |
| ILC | 3 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (4.1) | ||
| Other invasive carcinomaa | 2 (50.0) | 0 (0.0) | 1 (25.0) | 1 (25.0) | 4 (5.4) | ||
| Tumor diameterb | <20 mm | 14 (37.8) | 12 (32.4) | 7 (18.9) | 4 (10.8) | 0.213 | 37 (53.6) |
| ≥20 mm | 11 (34.4) | 6 (18.8) | 13 (40.6) | 2 (6.3) | 32 (46.4) | ||
| Lymph node metastasisb | Negative | 17 (35.5) | 14 (29.2) | 13 (27.1) | 4 (8.3) | 0.990 | 48 (67.6) |
| Positive | 8 (34.8) | 6 (26.1) | 7 (30.4) | 2 (8.7) | 23 (32.4) | ||
| ER | Negative (<1%) | 4 (16.7) | 7 (29.2) | 11 (45.8) | 2 (8.3) | 0.131 | 24 (32.4) |
| Positive (≥1%) | 21 (42.0) | 13 (26.0) | 12 (24.0) | 4 (8.0) | 50 (67.6) | ||
| PgR | Negative (<1%) | 6 (20.7) | 8 (27.6) | 12 (41.4) | 3 (10.3) | 0.226 | 29 (39.2) |
| Positive (≥1%) | 19 (42.2) | 12 (26.7) | 11 (24.4) | 3 (6.7) | 45 (60.8) | ||
| HER2 | Negative (0, 1+, 2+/no ISH amp) | 22 (42.3) | 13 (25.0) | 15 (28.8) | 2 (3.8) | 0.042* | 52 (70.3) |
| Positive (2+/ISH amp, 3+) | 3 (13.6) | 7 (31.8) | 8 (36.4) | 4 (18.2) | 22 (29.7) | ||
aTubulolobular carcinoma (n = 1), metaplastic squamous cell carcinoma (n = 1), mucinous carcinoma (n = 1), apocrine carcinoma (n = 1).
bPatient(s) data missing.
*P-value significant.
Invasive carcinoma of no special type (NST), invasive lobular carcinoma (ILC), in situ hybridization (ISH), amplification (amp).